IL307673A - מעכבי mek ושימושהם - Google Patents
מעכבי mek ושימושהםInfo
- Publication number
- IL307673A IL307673A IL307673A IL30767323A IL307673A IL 307673 A IL307673 A IL 307673A IL 307673 A IL307673 A IL 307673A IL 30767323 A IL30767323 A IL 30767323A IL 307673 A IL307673 A IL 307673A
- Authority
- IL
- Israel
- Prior art keywords
- mek inhibitors
- mek
- inhibitors
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175837P | 2021-04-16 | 2021-04-16 | |
| US202163262093P | 2021-10-05 | 2021-10-05 | |
| PCT/US2022/071732 WO2022221866A1 (en) | 2021-04-16 | 2022-04-15 | Mek inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307673A true IL307673A (he) | 2023-12-01 |
Family
ID=81579550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307673A IL307673A (he) | 2021-04-16 | 2022-04-15 | מעכבי mek ושימושהם |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4323066A1 (he) |
| JP (1) | JP2024514879A (he) |
| KR (1) | KR20230172548A (he) |
| AU (1) | AU2022258968A1 (he) |
| CA (1) | CA3215081A1 (he) |
| IL (1) | IL307673A (he) |
| WO (1) | WO2022221866A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230205A1 (en) * | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| SK287188B6 (sk) | 1999-12-10 | 2010-02-08 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AU2002253619B2 (en) | 2001-04-27 | 2007-05-17 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same active ingredients |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
| EA012240B1 (ru) | 2003-04-03 | 2009-08-28 | Семафор Фармасьютикалз, Инк. | Пролекарства ингибиторов киназы pi-3 |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| CA2531069A1 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| PL1761540T3 (pl) | 2004-05-13 | 2017-06-30 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta |
| ATE383360T1 (de) * | 2004-06-11 | 2008-01-15 | Japan Tobacco Inc | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| AU2006302179C1 (en) | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| SI2455382T1 (sl) | 2005-12-13 | 2017-03-31 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CL2007001165A1 (es) | 2006-04-26 | 2008-01-25 | Hoffmann La Roche | 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares. |
| NZ575650A (en) | 2006-09-22 | 2011-10-28 | Pharmacyclics Inc | Pyrimidinopyrazole derivatives as inhibitors of Bruton's tyrosine kinase |
| BRPI0808888B8 (pt) | 2007-03-12 | 2021-05-25 | Cytopia Res Pty Ltd | composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| CN102026999B (zh) | 2008-03-11 | 2014-03-05 | 因塞特公司 | 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物 |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX342591B (es) | 2008-12-09 | 2016-10-05 | Genentech Inc * | Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t. |
| AU2010289677B2 (en) | 2009-09-03 | 2014-07-31 | Merck Sharp & Dohme Llc | Anti-GITR antibodies |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| SI2949670T1 (sl) | 2009-12-10 | 2019-05-31 | F. Hoffmann-La Roche Ag | Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba |
| BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| CN103179985B (zh) | 2010-05-04 | 2016-10-26 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| MY162737A (en) | 2010-09-09 | 2017-07-14 | Pfizer | 4-1bb binding molecules |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (he) | 2011-04-15 | 2018-03-17 | ||
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗ｐｄ−ｌ１抗体及びその使用 |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US9573944B2 (en) * | 2012-03-14 | 2017-02-21 | Lupin Limited | Heterocyclyl compounds |
| KR20200011616A (ko) | 2012-05-11 | 2020-02-03 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| KR20200140400A (ko) | 2012-08-31 | 2020-12-15 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| ES2724578T3 (es) * | 2013-04-18 | 2019-09-12 | Shanghai Fochon Pharmaceutical Co Ltd | Ciertos inhibidores de proteína quinasas |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2017053706A1 (en) | 2015-09-23 | 2017-03-30 | The General Hospital Corporation | Tead transcription factor autopalmitoylation inhibitors |
| MY196809A (en) | 2015-12-24 | 2023-05-03 | Kyowa Kirin Co Ltd | (),()-unsaturated amide compound |
| JP2020518669A (ja) | 2017-05-03 | 2020-06-25 | ビバーチェ セラピューティクス，インク． | 非縮合三環式化合物 |
| KR20200019979A (ko) | 2017-06-23 | 2020-02-25 | 쿄와 기린 가부시키가이샤 | α, β 불포화 아미드 화합물 |
| ES2876293T3 (es) * | 2017-06-23 | 2021-11-12 | Cstone Pharmaceuticals | Compuesto cíclico similar a la cumarina como inhibidor de MEK y uso del mismo |
| CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| US11247082B2 (en) | 2018-05-04 | 2022-02-15 | ArchAngel Fire Systems Holdings, LLC | System, method, and apparatus for the suppression of fire growth |
| US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
| WO2019232216A1 (en) | 2018-05-31 | 2019-12-05 | Genentech, Inc. | Therapeutic compounds |
| JP7535500B2 (ja) | 2018-09-03 | 2024-08-16 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体 |
| WO2020081572A1 (en) | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
| JP7482861B2 (ja) | 2018-11-09 | 2024-05-14 | ビバーチェ セラピューティクス，インク． | 二環式化合物 |
| MA55322A (fr) | 2019-03-15 | 2022-01-19 | Massachusetts Gen Hospital | Nouveaux inhibiteurs à petites molécules de facteurs de transcription tead |
| WO2020214734A1 (en) | 2019-04-16 | 2020-10-22 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| EP3976192A1 (en) | 2019-05-31 | 2022-04-06 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| US20230381180A1 (en) | 2020-01-08 | 2023-11-30 | Icahn School Of Medicine At Mount Sinai | Small molecule modulators of ksr-bound mek |
| WO2022051567A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions |
| WO2022051565A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| WO2022051569A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
| WO2022051568A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
-
2022
- 2022-04-15 IL IL307673A patent/IL307673A/he unknown
- 2022-04-15 WO PCT/US2022/071732 patent/WO2022221866A1/en active Application Filing
- 2022-04-15 CA CA3215081A patent/CA3215081A1/en active Pending
- 2022-04-15 KR KR1020237039396A patent/KR20230172548A/ko unknown
- 2022-04-15 JP JP2023562904A patent/JP2024514879A/ja active Pending
- 2022-04-15 AU AU2022258968A patent/AU2022258968A1/en active Pending
- 2022-04-15 EP EP22720905.3A patent/EP4323066A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4323066A1 (en) | 2024-02-21 |
| CA3215081A1 (en) | 2022-10-20 |
| WO2022221866A1 (en) | 2022-10-20 |
| JP2024514879A (ja) | 2024-04-03 |
| KR20230172548A (ko) | 2023-12-22 |
| AU2022258968A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288381A (he) | מעכבי tead ושימושים בהם | |
| IL288384A (he) | מעכבי tead ושימושים בהם | |
| EP4087840A4 (en) | MEK INHIBITORS AND THEIR THERAPEUTIC USES | |
| FI3870579T3 (fi) | Tyk2-inhibiittoreita ja niiden käyttöjä | |
| IL289612A (he) | מעכבי hpk1 ושימושים בהם | |
| IL307673A (he) | מעכבי mek ושימושהם | |
| IL307187A (he) | מעכבי mk2 ושימושיהם | |
| IL286248A (he) | מעכבי tyk2 והשימוש בהם | |
| IL283409A (he) | מעכבי tyk2 ושימושים בהם | |
| IL282090A (he) | מעכבי tyk2 ושימושים בהם | |
| IL284799A (he) | מעכבי tyk2 ושימושים בהם | |
| IL300107A (he) | מעכבי hsd17b13 קווינאזולינון ושימושים בהם | |
| IL291217A (he) | מעכבי usp30 ושימושים שלהם | |
| GB202006792D0 (en) | Method and uses thereof | |
| IL286622A (he) | מעכבי prmt5 ושימושים בהם | |
| IL307165A (he) | מעכבי alk-5 ושימושים בהם | |
| IL314009A (he) | מעכבי parp1 והשימושים בהם | |
| IL311588A (he) | מעכבי lpxc ושימושים בהם | |
| IL316768A (he) | מעכבי mek ושימושים בהם | |
| GB202002010D0 (en) | Microtopographies and uses thereof | |
| IL291895A (he) | מעכבי mcl1ושימושים בהם | |
| GB202103872D0 (en) | Uses and methods | |
| IL280408A (he) | מעכבי cdk ושימושים בהם | |
| GB202007928D0 (en) | New uses and methods | |
| IL310209A (he) | מעכבי rock2 ושימושים שלהם |